Inhalable nanovesicles loaded with a STING agonist enhance CAR-T cell activity against solid tumors in the lung
Quick Facts
- Publication title: Inhalable nanovesicles loaded with a STING agonist enhance CAR-T cell activity against solid tumors in the lung
- Journal: Nat Commun
- Year: 2025
- DOI: 10.1038/s41467-024-55751-4
- PMID/PMCID: 39747173; PMC11695690
Research overview
Suppression of chimeric antigen receptor-modified T (CAR-T) cells by the immunosuppressive tumor microenvironment remains a major barrier to their efficacy against solid tumors. To address this, we develop an anti-PD-L1-expressing nanovesicle loaded with the STING agonist cGAMP (aPD-L1 NVs@cGAMP) to remodel the tumor microenvironment and thereby enhance CAR-T cell activity.
Key findings
Suppression of chimeric antigen receptor-modified T (CAR-T) cells by the immunosuppressive tumor microenvironment remains a major barrier to their efficacy against solid tumors.
To address this, we develop an anti-PD-L1-expressing nanovesicle loaded with the STING agonist cGAMP (aPD-L1 NVs@cGAMP) to remodel the tumor microenvironment and thereby enhance CAR-T cell activity.
Following pulmonary delivery, the nanovesicles rapidly accumulate in the lung and selectively deliver STING agonists to PD-L1-overexpressing cells via the PD-1/PD-L1 interaction.
This targeted delivery effectively avoids the systemic inflammation and poor cellular uptake that plague free STING agonists.
Echo Biotech Role
Echo Biotech contributed EV isolation and purification, EV characterization.
Related platforms: Exoomics®
Related services and capabilities: Cell-Culture Supernatant EV Isolation & Purification, EV Basic Characterization (TEM/NTA/WB)
References
Original publication: Inhalable nanovesicles loaded with a STING agonist enhance CAR-T cell activity against solid tumors in the lung Nature communications. 2025. DOI: 10.1038/s41467-024-55751-4. PMID/PMCID: 39747173; PMC11695690.